MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)

• Adult males and female patients with: Stage I, II or III who receive MammaPrint, with or without BluePrint testing.
• New Primary Lesion
• Excluded if: Metastatic Disease, Recurrent Disease, Stage 0 Disease

The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

• Newly diagnosed, Myleofibrosis Disease, primary or secondary MDS or AML or Idiopathic Cytopenia of Undetermined Significance (ICUS)
• The Myelofibrosis cohort includes 2 sub-cohorts:
  • 1. Patients receiving 1st active treatment for MR (N=400).
  • 2. Patients receiving 1st treatment MF related cytopenias (N=400)
• The MF cohort allows enrollment with DX of MDS/MPN, excluding JMML
• MDS / ICUS patients must be at least 18 years old
• AML patients must be at least 55 years old
• No active treatment (disease modifying) agents for ICUS or MDS prior to enrollment
• AML patients may have begun active, disease modifying treatment within 14 days of informed consent date
• Supportive care growth factors, transfusions, etc. are allowed prior to enrollment
• Confirmed diagnosis made up to 60 days prior to the date of informed consent.
• All supporting diagnostic reports go through central eligibility review.